Furthermore, the role of CYP2C19 polymorphisms (CYP2C19*2-rs4244285, CYP2C19*3-rs4986893) was investigated in 92 MM cases, 62 of which were treated with thalidomide and dexamethasone and 30 of which were treated with thalidomide combined with chemotherapy. The gene discussed is CYP2C19; the disease is Miyoshi myopathy.